Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v2.4.0.8
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
Mar. 31, 2014
Dec. 31, 2013
Current assets    
Cash      
Total current assets      
Fixed assets - net 1,036 1,230
Total Assets 1,036 1,230
Current liabilities    
Accounts payable 498,611 421,597
Accrued interest payable 300,361 268,950
Notes payable - current - related parties 573,516 573,516
Notes payable - current, net 636,099 612,342
Derivative liability 143,450 150,067
Stock subscription payable - current 26,000 26,000
Related party payables 220,765 190,765
Other payables 238,085 238,085
Total current liabilities 2,636,887 2,481,322
Notes payable - related parties 167,007 167,007
Total Liabilities 2,803,894 2,648,329
Stockholders' Deficit    
Common stock, $.00001 par value; 100,000,000 shares authorized;35,438,379 and 34,146,712 shares issued and outstanding at March 31, 2014 and December 31, 2013 respectively 355 342
Additional paid in capital 12,461,256 12,415,639
Deficit accumulated during the development stage (15,232,855) (15,032,660)
Total Transbiotec, Inc. stockholders' deficit (2,771,244) (2,616,679)
Noncontrolling interest (31,614) (30,420)
Total Stockholders' Deficit (2,802,858) (2,647,099)
Total Liabilities and Stockholders' Deficit $ 1,036 $ 1,230